Literature DB >> 7776971

Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability.

Z X Zhou1, M V Lane, J A Kemppainen, F S French, E M Wilson.   

Abstract

The molecular basis for the different physiological effects of testosterone (T) and dihydrotestosterone (DHT) was investigated using recombinantly expressed wild-type and mutant androgen receptor (AR). Rates of androgen dissociation from nuclear and cytoplasmic AR were compared with hormone- and concentration-dependent receptor degradation rates. T dissociates from AR 3 times faster than DHT or methyltrienolone (R1881) and is less effective in stabilizing the receptor. Analysis of AR deletion mutants and AR/glucocorticoid receptor chimeras indicates that the AR NH2-terminal domain has a specific role in stabilizing the receptor by slowing the rate of ligand dissociation and AR degradation. Amino acid mutations that abolish receptor dimerization, nuclear localization, or DNA-binding activity have no significant effect on androgen dissociation or AR degradation. A naturally occurring steroid-binding domain mutation (Val889 to Met) that causes androgen insensitivity, but does not alter equilibrium androgen binding affinity, lowered the androgen-binding capacity as a result of increased rates of androgen dissociation and AR degradation. Thus, AR stabilization and function require prolonged receptor occupancy with androgen, with a similar extent of stabilization observed at higher concentrations of faster dissociating androgens and lower concentrations of slower dissociating androgens. Retention of receptor-bound androgen is enhanced by an interaction between the AR NH2-terminal and steroid-binding domains. The ligand specificity and concentration dependence of receptor stabilization provide an explanation for physiological differences in the actions of T and DHT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7776971     DOI: 10.1210/mend.9.2.7776971

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  81 in total

1.  Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

Authors:  Makoto Sato; Mai Johnson; Liqun Zhang; Baohui Zhang; Kim Le; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

2.  Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats.

Authors:  Chetan Nandecha; Alok Nahata; Vinod Kumar Dixit
Journal:  Curr Ther Res Clin Exp       Date:  2010-10

3.  The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.

Authors:  Anthony J Saporita; Junkui Ai; Zhou Wang
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

Review 4.  Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment.

Authors:  Melanie J Grubisha; Donald B DeFranco
Journal:  Steroids       Date:  2013-02-01       Impact factor: 2.668

5.  Role for androgens in determination of ovarian fate in the common snapping turtle, Chelydra serpentina.

Authors:  Anthony Schroeder; Turk Rhen
Journal:  Gen Comp Endocrinol       Date:  2019-05-03       Impact factor: 2.822

6.  ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

Authors:  Ling Cai; Yi-Hsuan Tsai; Ping Wang; Jun Wang; Dongxu Li; Huitao Fan; Yilin Zhao; Rohan Bareja; Rui Lu; Elizabeth M Wilson; Andrea Sboner; Young E Whang; Deyou Zheng; Joel S Parker; H Shelton Earp; Gang Greg Wang
Journal:  Mol Cell       Date:  2018-09-27       Impact factor: 17.970

Review 7.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

Review 8.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

9.  NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor.

Authors:  Ayano Murai-Takeda; Hirotaka Shibata; Isao Kurihara; Sakiko Kobayashi; Kenichi Yokota; Noriko Suda; Yuko Mitsuishi; Rie Jo; Hirochika Kitagawa; Shigeaki Kato; Takao Saruta; Hiroshi Itoh
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

10.  20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.

Authors:  Bo Cao; Xichun Liu; Jing Li; Shuang Liu; Yanfeng Qi; Zhenggang Xiong; Allen Zhang; Thomas Wiese; Xueqi Fu; Jingkai Gu; Paul S Rennie; Oliver Sartor; Benjamin R Lee; Clement Ip; Lijuan Zhao; Haitao Zhang; Yan Dong
Journal:  Int J Cancer       Date:  2012-08-20       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.